Stimulants are often used to manage persistent obstructive sleep apnea (OSA)-related excessive daytime sleepiness (EDS), yet sleepiness often persists in conjunction with safety concerns associated with the use of stimulants, particularly in patients with medical comorbidities. Nonstimulant therapies have emerged to offer sustained long-term efficacy with favorable safety and tolerability profiles. Yet, clinicians are often challenged in identifying best practices to apply clinical trial updates to practice, particularly in complex patients. Data continue to emerge on the safety and efficacy of nonstimulants in reducing the burden of OSA-related EDS. Therefore, clinicians need to be aware of these clinical updates in order to develop personalized treatment plans to optimize patient outcomes.
Join Dr. Bogan in this third and final installment of a case-based CMEO BriefCase series on OSA-related EDS as he translates data from recent clinical trials to optimize treatment decision-making.
At the end of this CME/CE activity, participants should be able to apply data from recent clinical trials to optimize treatment decision-making.
This program is supported by an independent medical education grant from Jazz Pharmaceuticals.
Physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in sleep, pulmonology, psychiatry, neurology, and/or primary care.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Bogan reports the following financial relationships: Consultant: Harmony Biosciences, LLC; Jazz Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc. Grants: Axsome Therapeutics, Inc.; Eisai Inc.; Flamel Technologies; Fresca Medical, Inc.; Harmony Biosciences, LLC; Idorsia Pharmaceuticals; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc.; Philips; Suven Life Sciences; and Takeda Pharmaceuticals U.S.A., Inc. Speakers Bureau: Eisai Inc.; Harmony Biosciences, LLC; and Jazz Pharmaceuticals, Inc.
Dr. Rosenberg reports the following financial relationships: Advisory Board: Harmony Biosciences, LLC. Research Support: Idorsia Pharmaceuticals; Jazz Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc. Speakers Bureau: Jazz Pharmaceuticals, Inc.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Call us at 877.CME.PROS (877.263.7767).